BTK gene
AstraZeneca’s Calquence Gains FDA Approval as First-Line Treatment for Mantle Cell Lymphoma
AstraZeneca, Calquence, acalabrutinib, BTK inhibitor, mantle cell lymphoma, first-line treatment, FDA approval
BeiGene Secures Long-Term Protection for BRUKINSA with Patent Settlement Until 2037
BeiGene, BRUKINSA, patent settlement, MSN Pharmaceuticals, generic competition, market exclusivity, BTK inhibitor, cancer treatment
Abbott’s Esprit BTK Stent Demonstrates Sustained Benefits in Treating Severe Peripheral Artery Disease Below the Knee
Esprit BTK, dissolving stent, peripheral artery disease, below the knee, chronic limb-threatening ischemia, Abbott, LIFE-BTK trial, vascular health
Fenebrutinib Shows Promising Results in Relapsing Multiple Sclerosis Treatment
Fenebrutinib, Relapsing Multiple Sclerosis, BTK Inhibitor, Roche, Clinical Trials
Sanofi’s Tolebrutinib Shows Mixed Results in Multiple Sclerosis Trials
Sanofi, Tolebrutinib, Multiple Sclerosis, BTK Inhibitor, Clinical Trials
AstraZeneca’s New Calquence Combinations Show Promise in CLL Treatment: Potential to Shift Clinical Practice
AstraZeneca, Calquence, CLL, Chronic Lymphocytic Leukaemia, BTK Inhibitor, Venetoclax, Obinutuzumab, Clinical Practice, Fixed-Duration Treatment